Cancer Immunotherapy

IL-10 Suppresses the Immune Stimulatory Potential of B7.1 and B7.2

Published in Cancer Weekly, July 27th, 1998

Interleukin-10 (IL-10) suppresses the immune stimulatory potential of melanoma cells retrovirally transduced with the costimulatory molecules B7.1 and B7.2.

R. Dummer and colleagues from the University of Zurich Medical School, and the Basel Institute for Immunology, Switzerland, analyzed the immunostimulatory potential of B7.1- and B7.2-transduced human melanoma cell lines ("Immune Stimulatory Potential of B7.1 and B7.2 Retrovirally Transduced Melanoma Cells: Suppression by Interleukin 10," British Journal of Cancer, May 1998;77(9):1413-9).

"The goal of an effective vaccination therapy of cancer is to induce specific anti-tumor response mediated by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry